Combination chemotherapy with MOPP in children with recurrent brain tumors

Cangır, Ayten; Eys, Jan Van; Berry, D. H.; Hvizdala, Eva; Morgan, Samuel K.

doi:10.1002/mpo.2950040309

Cited by 44 publications

(11 citation statements)

References 9 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chemotherapy chosen for this study came from past experience with MOPP as a salvage treatment in brain tumors (4). Combination chemotherapy with MOPP has been used in the treatment of Hodgkin's disease in children as well as in adults.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MOPP regimen as primary chemotherapy for brain tumors in infants

Eys

Cangır

Coody³

et al. 1985

J Neuro-Oncol

Self Cite

View full text Add to dashboard Cite

Seventeen infants with central nervous system malignancies, all with tissue diagnosis, were treated with the combination chemotherapy nitrogen mustard, vincristine, procarbazine and a steroid (MOPP) as primary therapy following surgery. Diagnoses include: 7 astrocytomas (grade: 3-I, 3-II, 1-III), 6 medulloblastomas, 2 ependymoma/astrocytoma mixed, 1 ependymoma and 1 primitive neuroectodermal tumor. Fourteen were under 2 years of age, 2 between 2 and 3 years of age, and 1 between 3 and 4 years of age. Fifteen responded and 2 failed. Of the responders, 6 are in continuous complete remission (median duration 28.9+ months) and 9 are in relapse (median duration of remission 10.3 months). Of the 2 patients who failed and 9 who relapsed, 4 expired and 6 are living in partial or complete remission. We conclude that MOPP therapy is well tolerated, has effectiveness, and allows postponement of potentially debilitating radiotherapy in infants with brain tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

“…This is the so-called 'MOPP' regimen employed in Hodgkin's disease therapy. This regimen has proven effectiveness in salvage therapy for brain tumors in children who failed radiotherapy (4,5). A preliminary report on this approach has appeared (6).…”

Section: Introductionmentioning

confidence: 99%

MOPP regimen as primary chemotherapy for brain tumors in infants

Eys

Cangır

Coody³

et al. 1985

J Neuro-Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The studies reported by Cangir and co-workers (16,17) demonstrated that the combinations of MOPP and OPP (MOPP without nitrogen mustard) both have marginal activity in recurrent childhood brain tumors. The complete response rates were 9% and 3% for MOPP and OPP, respectively.…”

Section: Discussionmentioning

confidence: 99%

Combination chemotherapy with cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) in children with brain tumors

et al. 1985

View full text Add to dashboard Cite

The chemotherapeutic combination of cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) was used to treat 15 children with recurrent central nervous system tumors and seven children with newly diagnosed brainstem tumors. In patients with recurrent tumors, marginal activity was seen in various histologic types. COPP chemotherapy was clearly ineffective in patients with brainstem tumors. Toxicity consisted of mild to moderate myelosuppression and neurotoxicity.

show abstract

“…The major site of disease recurrence is the posterior fossa in greater than half of all patients, although extraneural sites of relapse are not infrequent, most commonly bone, lymph nodes, and lung. Treatment of recurrent metastatic disease has been unsatisfactory, although, a number of single agents and combination chemotherapy regimens have been shown to have significant activity in this setting [4][5][6][7][8][9][10][11][12][13][14][15]. In an effort to achieve long term disease-free survival and potential cure by exploiting the recognized chemosensitivity of this tumor, we employed salvage combination chemotherapy followed by high-dose ablative chemotherapy and allogeneic marrow transplantation in a young adult with recurrent metastatic medulloblastoma.…”

Section: Introductionmentioning

confidence: 99%

Treatment of recurrent metastatic medulloblastoma with intensive chemotherapy and allogeneic bone marrow transplantation

et al. 1992

View full text Add to dashboard Cite

We report here the first known case of a patient with recurrent metastatic medulloblastoma to achieve long-term disease-free survival following treatment with allogeneic bone marrow transplantation. A 27 year old white male with recurrent metastatic medulloblastoma involving lymph nodes, bone and bone marrow was treated with multi-agent chemotherapy followed by allogeneic bone marrow transplantation from an HLA-identical sibling donor. Morbidity was acceptable with moderate to severe mucositis in the immediate post transplant period and clinical grade I graft versus host disease of the skin controlled with modest doses of corticosteroids. The patient continues in unmaintained complete remission in excess of 28 months with a performance status of 100%. Allogeneic marrow transplantation following cytoreductive salvage chemotherapy is an aggressive strategy that may offer an improved likelihood of disease eradication and ultimate cure for poor prognosis patients with recurrent metastatic medulloblastoma.

show abstract

Combination chemotherapy with MOPP in children with recurrent brain tumors

Cited by 44 publications

References 9 publications

MOPP regimen as primary chemotherapy for brain tumors in infants

MOPP regimen as primary chemotherapy for brain tumors in infants

Combination chemotherapy with cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) in children with brain tumors

Treatment of recurrent metastatic medulloblastoma with intensive chemotherapy and allogeneic bone marrow transplantation

Contact Info

Product

Resources

About